Title Page
Title: Feasibility of Therapeutic Drug Monitoring of Sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer.
Short Title: Feasibility of sunitinib TDM in renal cancer
Khushboo Gandhia,1 , Amit Joshic,d,1, Parsshava Mehtaa , Murari Gurjara, Pallavi Raneb , Jyoti Sharmaa , Anand Patila,d , Manjunath Nookalaa,d , Vanita Noronhac,d , Kumar Prabhashc,d., Vikram Gota*a,d
1: Authors contributed equally to the present work
aDepartment of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Kharghar, Navi Mumbai-410210, India.
bDepartment of Biostatistics, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Kharghar, Navi Mumbai-410210, India.
cDepartment of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai-400012, India.
dHomi bhabha National Institute, Mumbai-400094, India
*To whom correspondence should be addressed: Dr. Vikram Gota, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Sector-22, Kharghar, Navi Mumbai-410210, India, Tel.: +91-22-27405493; Fax: +91-22-27405085; E-mail: vgota76@actrec.gov.in
Principal Investigator statement : The authors confirm that the Principal Investigator for this paper is Dr. Vikram Gota and that he had direct clinical responsibility for patients.
Key Words: Sunitinib; Therapeutic Drug Monitoring; Objective response; SU12662; Toxicity
Word count of text: 1727
Table Count: 1
Figure Count: 2